Dr. Richard Whitley, UAB distinguished professor, Gilead board member A University of Alabama at Birmingham-researched drug with potential for treating COVID-19 recently received FDA approval as a rare disease treatment, a distinction that looked like a windfall for its developer, California-based Gilead Sciences. But the company suddenly announced it was turning…
